Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

OSI Pharmaceuticals Ltd.

Division of Astellas Pharma Inc.

Latest From OSI Pharmaceuticals Ltd.

Appointments: ThermiGen, ReForm Biologics, Hookipa Biotech and Faron

This week’s roundup includes high-level appointments by Almirall, Hookipa Biotech and RXi Pharmaceuticals, in addition to CEO appointments by Karolinska Development and ReForm Biologics and various board announcements by companies including Faron and Redx.

Appointments BioPharmaceutical

Appointments: Sanofi, Fosun Kite, Milestone, Tocagen, GW Pharma, Hookipa and Bone Therapeutics

This week’s round-up includes the appointment of independent directors by Sanofi’s board of directors, CEO appointments by Fosun Kite Biotechnology and Milestone Pharmaceuticals as well as executive appointments by Tocagen, GW Pharmaceuticals, Bone Therapeutics and Tris Pharma.

Appointments BioPharmaceutical

Stockwatch: Flat Is The New Black For Lilly And Sanofi

A lackluster fourth-quarter earnings season at least didn't get any worse with the reports of Merck, Lilly, Sanofi and GSK. Flat earnings guidance might be considered to be an improvement on guidance cuts, but financial guidance that depends on currency effects and the absence of generic competition may ultimately be unreliable.

Commercial Companies

Stockwatch: Valeant Attempts To Divert Attention

A well-orchestrated build-up to the annual J.P. Morgan Healthcare Conference and subsequent rush of fundraisings was helped by the acquisition of Ariad by Takeda early last week. But the good times were derailed by a drug-pricing diversion, unleashed by the US president-elect.

Commercial Companies
See All

Company Information

  • Industry
  • Contract Research, Toxicology Testing-CRO
  • Therapeutic Areas
  • Alias(es)
  • Aston Molecules
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • UK
  • Parent & Subsidiaries
  • Astellas Pharma Inc.
  • Senior Management
  • John A Slack, VP, Dev.
    Charmaine Quarterman, Dir., Dev.
    John Murray, VP, Head of Medicinal Chemistry
    Eric Collington, VP, Corporate Strategic Affairs
  • Contact Info
  • OSI Pharmaceuticals Ltd.
    Phone: (44) 121359 1100
    10 Holt Court South
    Birmingham, B7 4EJ
    UK
Advertisement
Advertisement
UsernamePublicRestriction

Register